GO Main Menu Go Main Contents Go Bottom Menu

CelltrionHealthcare

gnb show

MENU

Gnb close

Press Release

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients 2023-12-11

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients   Ventegra® will list VEGZELMA®(bevacizumab-adcd) on its national formulary that serves more than 400 clients and more than 13 million members and patients in the U.S. Celltrion USA completes a contract ...

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs 2023-10-26

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs YUFLYMA® (adalimumab-aaty) was first approved by the Food and Drug Administration on May ...

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease 2023-10-23

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease ZYMFENTRA™ is the first and only FDA-approved subcutaneous (SC) formulation of i...

게시물 검색
  • 95
    Celltrion USA receives U.S. FDA approval for its o..
    Celltrion USAreceives U.S. FDA approval for its oncology biosimilar Vegzelma® (bevacizumab-adcd) for the treatment of six types of cancer · Vegzelma® is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA · Vegzelma…
    2022-09-28
  • 94
    European Commission approves Celltrion Healthcare’..
    European Commission approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the treatment of multiple types of cancer · Vegzelma™ offers European patients living with certain types of breast, lung, renal, colon, rectum…
    2022-08-19
  • 93
    Celltrion Healthcare receives CHMP positive opinio..
    Celltrion Healthcare receives CHMP positive opinion for biosimilar bevacizumab, Vegzelma™ (CT-P16) • Vegzelma™ (CT-P16), a biosimilar candidate referencing Avastin®(bevacizumab)1, is Celltrion’s third oncology biosimilar…
    2022-06-27
  • 92
    New data show statistically greater improvements i..
    New data show statistically greater improvements in clinical outcomes with subcutaneous infliximab, compared to intravenous infliximab, in patients with rheumatoid arthritis - Presented today at EULAR 2022, data from a new post-hoc analysis s…
    2022-06-02
  • 91
    Celltrion Healthcare wins tender to supply Remsima..
    Celltrion Healthcare wins tender to supply Remsima® to the Brazilian Federal Government • Remsima® is the third biosimilar product for Celltrion Healthcare to win tender in Brazil following Truxima® and Herzuma® • The company will be supplying R…
    2022-03-24
  • 90
    Switching to subcutaneous infliximab leads to high..
    Switching to Subcutaneous Infliximab Leads to Higher Trough Level and Low Risk of Relapse in Patients with Inflammatory Bowel Disease - New data from the REMSWITCH study shows switching from intravenous (IV) to subcutaneous (SC) infliximab leads t…
    2022-03-02
  • 89
    Celltrion Submits IND Application to Initiate a Gl..
    Celltrion Submits Investigational New Drug (IND) Application to Initiate a Global Phase III Clinical Trial Evaluating an Inhaled COVID-19 Antibody Cocktail Therapy Celltrion submitted an IND application for a global Phase III clinical trial of …
    2022-02-07
  • 88
    Celltrion announces positive results for its cockt..
    Celltrion announces positive results for its cocktail therapy candidates including neutralisation data against Omicron variant CT-P63 demonstrated a well- established safety profile in the global Phase I trial CT-P63 maintained str…
    2022-01-03
  • 87
    TGA grants provisional approval for Celltrion’s re..
    TGA grants provisional approval for Celltrion’s regdanvimab (regkirona) ·The monoclonal antibody treatment is provisionally approved for the intravenous treatment of mild-to-moderate COVID-19 patients in Australia[1] December 7, 2021,INCHEON, KO…
    2021-12-07
  • 86
    Celltrion accelerates development of nebulised coc..
    Celltrion accelerates development of nebulised cocktail therapy (CT-P63 in combination with CT-P59) using its antibody platform to tackle new COVID-19 variants Celltrion previously completed phase I clinical trials with a nebulised f…
    2021-11-29